ARTICLE | Company News

Merck to acquire cCAM

July 29, 2015 1:44 AM UTC

Merck & Co. Inc. (NYSE:MRK) will acquire cancer immunotherapy play cCAM Biotherapeutics Ltd. (Misgav, Israel) in a deal worth up to $605 million.

The acquisition gives Merck lead candidate CM-24, a humanized IgG4 mAb targeting carcinoembryonic antigen (CEA)-related cell adhesion molecule 1 ( CEACAM1; CD66a) that is in Phase I testing to treat advanced or recurrent solid tumors. cCAM will receive $95 million up front and up to $510 million in milestones. ...